1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. IMMUNITYBIO INC
ImmunityBio Inc XNAS: IBRX
7.34 0.42 (6.07%)
80.4M

XNAS 22 Jan, 2026 4:19 PM (EST)

Watchlist

Portfolio

Alert

Regulatory Tailwinds
ImmunityBio rises on Tuesday as FDA clears approval path for its bladder cancer drug, ANKTIVA See details

ImmunityBio Inc Splits, Dividends and Corporate Actions

Check all corporate actions such as stock splits, dividends, mergers & acquisitions, and board meeting announcements for ImmunityBio Inc